Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maltodextrin + caffeine is a combination product typically used as a dietary supplement or as part of sports and cognitive performance products. Caffeine is a central nervous system stimulant of the methylxanthine class, acting primarily as a non-selective adenosine receptor antagonist, with additional effects on phosphodiesterase inhibition and catecholamine release, leading to increased alertness, enhanced exercise performance, and cognitive effects[2][3][5]. Maltodextrin is a polysaccharide carbohydrate, easily digestible and commonly used as a food additive for energy replenishment, with no known direct pharmacological activity but potentially able to affect brain reward pathways via oral sensing and rapid glucose availability[4][1][3][5]. The combination has been studied in the context of mouth rinses and ingestion for reduction of cognitive fatigue and improved exercise performance[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maltodextrin + caffeine.